Today: 18 June 2026
Browse Category

NASDAQ:AKRO 9 October 2025 - 14 December 2025

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk shares rebounded this week, rising about 7% in both Copenhagen and U.S. trading after EU regulators backed a higher-dose Wegovy, Ozempic launched in India at a lower price, and the company closed its Akero Therapeutics acquisition. The week began with a sharp selloff on competition fears and a Wall Street downgrade before sentiment reversed midweek.
14 December 2025
····
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk will pay up to $2.1 billion to license Omeros’s experimental MASP-3 inhibitor zaltenibart for rare blood and kidney disorders. Omeros receives $340 million upfront, with additional milestone and royalty payments possible. Omeros shares jumped about 65% on the news, while Novo’s stock fell 1.5%. The deal is expected to close by Q4 2025.
15 October 2025
···
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero shares jumped nearly 19% to $55 on October 9, 2025 after Novo Nordisk announced a $5.2 billion buyout at $54 per share plus a $6 contingent payment. Novo will pay $4.7 billion upfront and another $500 million if Akero’s lead drug, efruxifermin, wins FDA approval by 2031. The deal has board approval and is expected to close by late 2025, pending regulatory and shareholder clearance.
9 October 2025
···
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion, paying $54 per share in cash plus a potential $6 per share if Akero’s lead drug wins U.S. approval by 2031. Akero’s efruxifermin, in Phase 3 trials for fatty liver disease, has shown reversal of liver fibrosis in mid-stage studies. Akero shares jumped 19% on the news, while Novo shares were little changed. The deal is expected to close by year-end.
9 October 2025
··

Stock Market Today

  • Accenture Shares Decline After Missed Revenue Forecast Despite $4.18 Billion Cybersecurity Investment
    June 18, 2026, 9:50 AM EDT. Accenture shares fell sharply in premarket trading following a lowered full-year revenue growth forecast of 3% to 4%, missing Wall Street estimates. The consulting giant posted $18.7 billion in Q3 revenue, a 6% increase, yet new bookings declined. Despite the cutback, Accenture announced a $4.18 billion cybersecurity acquisition targeting critical industrial systems, aiming to bolster operational technology security. CEO Julie Sweet highlighted growing demand for large-scale reinventions and emerging AI transformation deals, but investors remain cautious amid questions over AI's impact on consulting roles. The deal includes Dragos, runZero, and NetRise, expected to bring $208 million in annual recurring revenue by mid-2026. Concerns persist over U.S. federal contract pressures and weaker IT budgets affecting growth outlook.

Latest articles

Kroger edges down after it sticks to 2026 guidance

Kroger edges down after it sticks to 2026 guidance

18 June 2026
Kroger shares fell about 3% in premarket trading after first-quarter adjusted profit missed estimates by a cent despite a sales beat, as margin pressure from price cuts and higher transport costs raised investor doubts about CEO Greg Foran’s strategy to win back shoppers from Walmart and Costco.
HIVE Digital shares jump in premarket after $220 million Bell-Cohere AI contract

HIVE Digital shares jump in premarket after $220 million Bell-Cohere AI contract

18 June 2026
HIVE Digital Technologies surged 11% in premarket trading after its BUZZ HPC unit landed a $220 million, three-year GPU cloud contract with Bell AI Fabric and Cohere, expected to add $70 million in annual recurring revenue and boost contracted AI-compute revenue above $100 million, as investors look for growth beyond bitcoin mining.
AT&T falls in early trading on CFO transition, spotlight on fiber costs

AT&T falls in early trading on CFO transition, spotlight on fiber costs

18 June 2026
AT&T shares slipped to $22.37 premarket as investors weighed CFO Pascal Desroches’ year-end retirement and Jennifer Biry’s 2027 succession amid heavy fiber and 5G spending, ongoing wireless competition from Verizon, and looming risks from SpaceX’s Starlink; next financial update set for July 22.
Go toTop